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Summary
In a prospective clinical study of 50 patients with Dengue Shock
Syndrome (DSS), we investigated the association of tumor necrosis
factor-  (TNF- ), interleukin-1  (IL-1 ), IL-1 receptor antagonist 
(IL-1Ra), and IL-6 with activation markers of coagulation (F1+2 and
TATc) and fibrinolysis (t-PA, PAPc, and D-dimer). We found that
TNF- , IL-1  and Il-1Ra, but not IL-6, concentrations were elevated in
the circulation during the early stage of infection and at discharge from
hospital. TNF-  was significantly associated with D-dimer, an activation
marker of fibrinolysis (p < 0.003), but not with activation markers of
coagulation. IL-1  was significantly associated with t-PA (p < 0.03).
IL-1Ra was significantly associated with F1+2, TATc (p < 0.04 and 
p < 0.02, respectively), whereas IL-6 was significantly associated with
both, activation markers of coagulation (F1+2; p < 0.03) and fibrinolysis
(PAPc; p = 0.002). Our data are in line with studies in bacterial sepsis.
In severe dengue virus infection the same cytokines are involved in the
onset and regulation of hemostasis. 
Introduction
The association between infection and activation of coagulation and
fibrinolysis has been studied extensively in Gram negative-sepsis and
endotoxemia (1). Activation of coagulation, as reflected by increasing
plasma levels of prothrombin fragment 1 and fragment 2 (F1+2) and
thrombin-antithrombin complexes (TATc), and activation of fibrinolysis,
as reflected by increasing plasma levels of tissue plasminogen activator
(t-PA) and plasminogen activator inhibitor type 1 (PAI-1), have been
detected in sepsis (2-4) and in experimental endotoxemia in humans (5,
6). Cytokines appear to play a crucial role in the initiation of coagulation
and fibrinolysis under these circumstances (1). Tumor necrosis factor  
(TNF- ), interleukin-1  (IL-1 ), and interleukin-6 (IL-6) seem to be
the most prominent mediators in this respect (1, 6-10).
Dengue hemorrhagic fever (DHF) is a severe form of the infection
caused by any of four serotypes of the dengue virus. It is characterized
by fever, thrombocytopenia, bleeding manifestations ranging from mild
to severe, and evidence of plasma leakage. According to the 1997
WHO criteria, dengue shock syndrome (DSS) is defined as DHF with
signs of circulatory failure, including narrow pulse pressure (20 mm
Hg) and hypotension (DHF grade III) or frank shock (DHF grade IV)
(11, 12). Plasma leakage and bleeding are the two major pathophysio-
logical changes in DHF/DSS, determining the severity of disease 
(11-14). Little is known about the pathogenesis of bleeding in DHF/
DSS and in an analogy to sepsis it is attractive to speculate that cyto-
kines are key mediators. Preexisting heterotypic dengue antibodies 
augment dengue virus infection of monocytes or macrophages (15). An
increased number of dengue virus-infected monocytes may result in T-
lymphocyte activation; the activation of both types of cell may result in
the production of elevated levels of the aforementioned cytokines (16). 
We designed a prospective clinical study to investigate the association
of cytokines with activation markers of coagulation and fibrinolysis in
DSS. We investigated those cytokines which are known to play a role
in the activation of coagulation and fibrinolysis in bacterial sepsis. 
Patients and Methods
Study Setting
The study was executed in Dr. Kariadi Hospital, Semarang, Indonesia, the
university hospital of Diponegoro University. The research protocol was reviewed
and approved by the institutional Review Board of the Dr. Kariadi Hospital.
Written informed consent was obtained from children’s parents or legal 
guardians.
Patients
Between June and November 1996, during an outbreak of dengue in 
Indonesia, 50 consecutive children with the clinical diagnosis of DSS, and who
had been admitted to the Paediatric Intensive Care Unit, were enrolled in the
study. The diagnosis of DSS (DHF grade III and grade IV) was based on WHO
criteria (1997) (11). The assessment of decreased consciousness was based on
the Glasgow coma scale (17). Only children aged ≥ 3 years were included. 
Patient Monitoring 
Thorough clinical assessments were performed daily during hospitalization,
using a medical record form. Laboratory tests to support clinical management
included blood cell counts, tests for hemostasis (prothrombin time and 
activated partial thromboplastin time) as well as biochemical tests for kidney
and liver functions and electrolyte status. 
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Specimen Collection 
Blood specimens were collected in vacutainer tubes (Becton Dickinson,
Rutherford, NJ 07417). Specimens for cytokine assays were collected in the
acute phase of disease (on day of admission: day 0, on day 1 and 2), and on day
7 or the day of discharge if the patient was hospitalized for less than 7 days.
Four ml of blood were collected into sterile tubes containing EDTA in each 
patient. To this tube 125 µL of aprotinin (Trasylol, Bayer, Leverkusen, 
Germany; final concentration 625 kallikreine inactivating units/mL) was 
added through the stopper by a tuberculin needle and syringe. The tube was
centrifuged directly at 1250 g for 10 min, and thereafter at 15000 g for 1 min to
remove platelets. The plasma was stored in aliquots at –80° C until assayed for
cytokines. 
Blood samples for analysis of coagulation and fibrinolysis were collected on
the same days as the samples for cytokines. Venous blood (9 vol.) for measurement
of F1+2, TATc and D-dimers was drawn into vacutainer tubes containing 0.105
M sodium citrate (1 vol.). For measurement of PAPc, t-PA, blood was collected
in siliconized vacutainer tubes containing Polybrene (Janssen Chimica, Belgium)
and EDTA (0.05% w/v, and 10 mM, respectively, final concentrations) to 
prevent in-vitro complex formation. All blood samples were immediately 
immersed in melting ice and subsequently centrifuged at 4° C for 20 min at
1600   g. Plasma samples were stored at –80° C until assayed. 
To collect appropriately timed specimens for serological assays (≥ day 6 
after onset of fever) (18-21), 2 ml of blood was collected on day of admission
and at discharge. Blood was centrifuged 1000-1500 rpm for 10 min, afterwards,
serum was transferred to screw cap Eppendorf tubes and stored at –80° C, until
assayed. For the transport from Indonesia to The Netherlands (which lasts 
longer than 15 h) the samples for cytokines, coagulation, fibrinolysis, and 
serological assays were kept on dry ice.
Cytokine Assays
TNF- , IL-  and IL-1Ra were measured in duplicate by nonequilibrium 
radioimmunoassay (RIA) (22). Recombinant human TNF- , IL-1  and IL-1Ra
were calibrated against standards provided by the National Institute of Biolo-
gical Standards and Control (Potters Bar, UK), with the sensitivity of the assay
with 100 µl sample of 40 pg/ml, 40 pg/ml, and 80 pg/ml, respectively. IL-6 was 
measured with ELISA obtained from the Central Laboratory of the Netherlands
Red Cross Blood Transfusion Service, Amsterdam, The Netherlands, according
to manufacturer’s instruction; circulating concentrations exceeding 10 pg/ml
were considered to be elevated.
Coagulation and Fibrinolysis Assays 
F1+2 and TATc levels were determined with the use of commercially 
available ELISA kits, according to the manufacturer’s instructions (Enzygnost
F1+2 micro and TAT micro, Dade Behring, Marburg, Germany). For the 
measurement of D-dimer levels, the TintElize D dimer ELISA from Biopool
(Sweden) was used, according to the manufacturer’s instructions. t-PA was
measured with sandwich ELISA kits using specific monoclonal antibodies as
described before (23). PAPc was measured with radioimmuno-assay as 
described previously (24). 
Serological Assays 
The diagnosis of dengue infection was confirmed by serological assays. A
capture and indirect enzyme-linked immunosorbent assay (ELISA) detected
Table 1 Characteristics in 50 patients with dengue shock syndrome
Table 2 Median circulating plasma concentrations
(range) of TNF- , IL- , IL-1Ra and IL-6 on day of 
admission (D0), the following two days (D1, D2) and
on day 7 or at discharge if earlier (D7/discharge) in 
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dengue specific IgM and IgG antibodies in serum samples, according to a 
previously described procedure (25).
Statistical Analysis
Continuous data were described as mean with SD or median with range. 
Nominal data were described as percentage (%). Multiple linear regression
analysis was done to determine the association between cytokines and activation
markers of coagulation and fibrinolysis on the day of admission. P values of
less than 0.05 were considered to indicate statistical significance. All statistical
analyses were performed with SPSS for Windows, version 9.0. 
Results
Between June and November 1996, 50 children with a clinical 
diagnosis of DSS, were enrolled in the study. Baseline characteristics of
the patients are listed in Table 1. Thirteen patients (26%) died during
follow up on the intensive care unit. The clinical diagnosis was confirmed
by serological assay in all patients, either by an IgM response or a 
fourfold rise in IgG titres. Antibody profiles were typical for secondary
dengue infection. 
Plasma Concentrations of Cytokines in the Course of DSS
The circulating plasma concentrations of TNF- , IL1 , IL-1 Ra, and
IL-6 were assayed on the day of admission (day 0), on day 1 and 2 
after admission, and on day 7 after admission or at discharge if this was
earlier than day 7. As shown in Table 2, concentrations of TNF-  and
IL-1  were mildly elevated and concentrations of IL-1Ra were 
moderately elevated during the early stage of infection and at discharge.
The median plasma concentrations of IL-6 were low during the 
observation period, although three patients had extremely high plasma
concentrations.
Activation of Coagulation and Fibrinolysis 
As shown in Table 3, F1+2 and TATc were persistently high from
admission to discharge, reflecting activation of coagulation. Also, 
persistently elevated levels of t-PA, PAPc, and D-dimer were found 
during the study period, reflecting activation of the fibrinolytic system.
Association of Plasma Concentrations of Cytokines with Activation
Markers of Coagulation and Fibrinolysis
As shown in Table 4, TNF-  was significantly associated with 
D-dimer, an activation marker of fibrinolysis, but not with activation 
markers of coagulation. IL-1  was significantly associated with 
activation marker of fibrinolysis t-PA; the regression coefficient ( ) for
t-PA of IL-1  was 4.05, meaning that for every additional 10 pg IL-1 ,
t-PA increases 4.05 ng/ml. IL-1Ra was significantly associated with 
activation markers of coagulation F1+2 as well as TATc. The regression
coefficient ( ) for F1+2 of IL-1Ra was 0.11, meaning that for every 
additional 100 pg/ml of IL-1Ra, F1+2 increases 0.11 nMol. IL-6 was
significantly associated with F 1+2, an activation marker of coagulation
and with PAPc, an activation marker of fibrinolysis. The regression 
coefficient ( ) for F1+2 of IL-6 was 0.05, implying that for every 
additional 1000 pg/ml of IL-6, F1+2 increases 0.05 nMol. Similarly,  
for PAPc of IL-6 was 0.17, and for D-dimer of TNF-  was 13.77. This
means that for every additional 1000 pg of IL-6, PAPc increases 0.17
nMol, and for every additional 10 pg of TNF- , D-dimer increases
13.77 ng/ml. 
Discussion 
The present study in severe dengue virus infection demonstrates,
that cytokines are associated with activation markers of coagulation and
fibrinolysis. 
Table 3 Median plasma concentrations (range) of 
activation markers of coagulation and fibrinolysis on
day of admission (D0), the following two days (D1,
D2) and on day 7 or at discharge if earlier (D7/ 
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TNF-  was significantly associated with D-dimer, a marker of 
fibrinolysis, but not with activation markers of coagulation. Studies in
bacterial infection have clearly indicated the role of TNF-  in the 
activation of the fibrinolytic system, but the role of TNF-  in the 
activation of the coagulation system seems to be less direct. A single 
intravenous injection of recombinant TNF into human volunteers 
induced activation of the common pathway of the coagulation cascade,
resulting in thrombin formation, as reflected by elevated plasma levels
of F1+2 (3), and activation of the fibrinolytic system characterized by
increased levels of urokinase-type PA (u-PA) and t-PA, followed by
PAI-1 (4). An injection of E. coli endotoxin induced increased levels of
TNF-  and IL-6, and resulted in activation of fibrinolysis as reflected
by increased levels of t-PA, PAPc, which was subsequently offset by 
release of PAI-1, and a long-lasting onset of coagulation activation 
characterized by increase of prothrombin F1+2 and TATc (9). 
However, further studies have demonstrated that anti-TNF treatment
did not affect endotoxin-induced coagulation activation (26-28), but did
inhibit the activation of the fibrinolytic system in animal and human
models with low-grade endotoxaemia (26, 27, 29). Thus our findings in
DHF are in line with these findings in endotoxemia. 
We demonstrated that IL-1  was significantly associated with tPA,
a marker for activation of fibrinolysis. The role of IL-1  in the activation
of coagulation as well as fibrinolysis has been demonstrated by injection
of IL-1 , or, indirectly by injection of IL-1Ra (5, 6). Infusion of IL-1
into baboons induced activation of the fibrinolytic system, reflected by
increased levels of t-PA, and subsequently the offset of fibrinolysis by
PAI-1, followed by the activation of coagulation, characterized by 
increased levels of TATc (5). Administration of IL-1Ra in baboons
with lethal bacteremia, and in patients with sepsis have significantly 
attenuated the activation of coagulation and fibrinolysis (6). 
We also found that IL-1Ra was significantly associated with the 
activation markers of coagulation F1+2 and TATc, leading to the 
conclusion that the regulation of coagulation and fibrinolysis by IL-1 
and IL-1Ra in this severe viral infection is similar to that in sepsis. 
We demonstrated that IL-6 is significantly associated with activation
markers of both coagulation and fibrinolysis. The role of this cytokine
in the activation of coagulation has been demonstrated by injection of
recombinant IL-6, as well as by administration of anti-IL-6 antibody.
Infusion of recombinant IL-6 into patients with renal cell carcinoma 
resulted in increased levels of F1+2 and TATc, while fibrinolysis was
not clearly affected (30).
In the present study we found that the median levels of IL-6 were
normal, but with extremely high values in 3 patients (5823, 86000 and
199000 pg/ml). Two of these 3 patients died and in these two patients,
very high levels of TNF-  (2500 and 2500 pg/ml), IL-1Ra (2500 and
2500 pg/ml), and F1+2 (7.51 and 14.2 nMol/l, normal <1.1 nMol/l) 
were found. The very high levels of F1+2 reflect the degree of coagulation
activation, which may result in a considerable fibrin formation, leading
to multiorgan failure and ultimately to death. 
We conclude that in dengue shock syndrome the same cytokines are
involved in the onset and regulation of coagulation and fibrinolysis as
in bacterial infections.
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